Source: International Congress 2018 – Experimental research in pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Mendes Ferreira (Leuven, Belgium), R. Adao (Porto, Portugal), R. Quarck (Leuven, Belgium), C. Belge (Leuven, Belgium), M. Delcroix (Leuven, Belgium), C. Bras-Silva (Porto, Portugal). Activation of the Beta-3 adrenoceptor in experimental pulmonary hypertension. 3063

Member's Comments

No comment yet.

Related content which might interest you: Inhalation of endothelin receptor blockers in pulmonary hypertension Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008 Endothelin receptor antagonists in pulmonary arterial hypertension Source: Eur Respir J 2008; 31: 407-415 Year: 2008 Dual endothelin receptor antagonism: setting standards in PAH Source: Eur Respir Rev 2008; 17: 13-18 Year: 2007 NTP42, an antagonist of the thromboxane receptor, attenuates experimentally-induced pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench Year: 2019 Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment Source: Eur Respir J 2011; 38: 851-860 Year: 2011 Effects of AT1 receptor blockade on pulmonary and systemic manifestations in a COPD/emphysema mouse model Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009 Switch of patients with pulmonary arterial hypertension after withdrawal of the endothelin receptor antagonist sitaxentan Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure Source: Eur Respir J 2011; 37: 578-586 Year: 2011 Echocardiographyc and histomorphometric assessment of the effects of pharmacological antagonism of endothelin receptors in the Sugen 5416/hypoxia rat model of pulmonary hypertension Source: International Congress 2018 – Experimental research in pulmonary hypertension Year: 2018 Single centre experience with endothelin receptor blockade in pulmonary hypertension Source: Annual Congress 2004 - Pulmonary hypertension Year: 2004 LSC Abstract – Glutamatergic signaling through pulmonary vascular NMDA receptors in pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015 Adrenergic receptor blocker reverses cardiac metabolic remodeling and improves right ventricular function in experimental pulmonary hypertension Source: Annual Congress 2011 - Molecular: pathology of infectious and inflammatory lung disease Year: 2011 Endothelin-a receptor antagonists reduce eNOS gene expression in rats with chronic hypoxic pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 271s Year: 2003 Sustained efficacy with the selective endothelin-A receptor antagonist, sitaxsentan, after two years of therapy in patients with pulmonary arterial hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 204s Year: 2005 NMDA receptor activation promotes vascular remodeling and pulmonary arterial hypertension Source: International Congress 2018 – Pathobiology of pulmonary hypertension Year: 2018 Endothelin: setting the scene in PAH Source: Eur Respir Rev 2008; 17: 3-7 Year: 2007 Peripheral airway dysfunction persist after endothelin receptor antagonist therapy in patients with idiopathic pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary circulation Year: 2009 Endothelin-1 receptor antagonists prevent the development of pulmonary emphysema in rats Source: Eur Respir J 2010; 35: 904-912 Year: 2010 Bosentan therapy for portopulmonary hypertension Source: Eur Respir J 2005; 25: 502-508 Year: 2005 Pulmonary hypertension in COPD Source: Eur Respir Mon 2013; 59: 189-205 Year: 2013